93 results about "Atherosclerosis aorta" patented technology

The invention discloses a scorpion antiatherosclerosis polypeptide and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. The anti-atherosclerosis polypeptide of the Buthus martensii Karsch is one of a peptide fragment 1, a peptide fragment 2, a peptide fragment 3, a peptide fragment 4, a peptide fragment 5, a peptide fragment 6 and a peptide fragment 7, and the amino acid sequences are respectively shown as SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7. The anti-atherosclerosis polypeptide of the Buthus martensii Karsch is an anti-atherosclerosis polypeptide of the Buthus martensii Karsch. The anti-atherosclerosis polypeptide obtained by screening can significantly reduce oxidative damage and reduce lipid deposition, especially peptide fragment 5; a theoretical basis is provided for medicinal development of the scorpion antiatherosclerosis peptide, and a potential antiatherosclerosis mechanism of the scorpion antiatherosclerosis peptide is disclosed.

The application discloses medical use of gelated cells loaded with sulfonated chitosan in treatment of atherosclerosis, and belongs to the technical field of biological medicine. The gelated cells loaded with sulfonated chitosan take macrophages as host cells, and intracellular cross-linking forms a photocrosslinking hydrogel network composed of methacrylated hyaluronic acid and sulfonated chitosan. The gelated cells completely retain cell membrane structure and membrane surface protein expression, lose the proliferation ability, and have excellent blood lipid selective adsorption capacity and foam cell lipid metabolism regulation capacity. In-vivo and in-vitro experiments prove that the gelated cells can significantly reduce blood lipid levels of atherosclerosis model animals, reduce aortic plaque area, and have good biological safety, thereby providing a new strategy and candidate drug for prevention and treatment of atherosclerosis, and having a good clinical application prospect.

Provided are a Lactobacillus plantarum strain, Lactobacillus plantarum PDG8, and a composition thereof. Also provided are methods using Lactobacillus plantarum PDG8 or a composition thereof for treating a cardiovascular disease such as atherosclerosis.

The present invention relates to pharmaceutical composition(s) comprising particles comprising one or more compounds which are inhibitors of microsomal triglyceride transfer protein and / or apolipoprotein B (Apo B) secretion, wherein at least 50% of the particles are characterized by a volume particle fraction less than 10 μm, more preferably less than 5 μm, more preferably less than 2.5 μm. The pharmaceutical composition can be useful for the prevention and treatment of various diseases, particularly atherosclerosis and its clinical sequelae, for lowering serum lipids, and related ailments. The invention further relates to methods of treating diseases, such as hypertriglyceridemia, hyperchylomicronemia, atherosclerosis, obesity, and related conditions using the compounds. A method for decreasing apolipoprotein B (apo B) secretion is also provided.

The invention discloses a medicinal moxa composition for preventing and treating atherosclerosis and suppurative bacterial infection co-disease. The medicinal moxa composition comprises coptis chinensis, radix rehmanniae, polygala tenuifolia, juncus effuses and moxa. The medicinal folium artemisiae argyi composition disclosed by the invention can be used for effectively preventing and treating atherosclerosis and skin suppurative bacterial infection co-diseases through a multi-target synergistic effect. The medicinal moxa composition has the core effects of clearing away heart-fire, inducing diuresis for treating stranguria and promoting blood circulation to remove meridian obstruction, and forms a complete treatment system which uses cold and warm as well as treats both symptoms and root causes by purging fire for removing toxin through coptis chinensis, clearing heat and cooling blood through radix rehmanniae, soothing nerves and promoting intelligence through polygala, inducing diuresis and conducting heat downward movement through juncus effuses and combining moxa floss for warming and dredging meridians, eliminating cold to stop pain, resisting bacteria and diminishing inflammation. By inhibiting inflammatory factors, regulating epithelial cell proliferation and reaction to oxidative stress, regulating fluid shear force, atherosclerosis and Kaposi sarcoma-related herpesvirus infection-related pathways and other mechanisms, the medicinal folium artemisiae argyi composition realizes synergistic prevention and treatment of atherosclerosis and skin infection, and provides a basis for co-disease treatment.

The invention belongs to the technical field of animal model construction, and particularly relates to a method for constructing a silicosis-related atherosclerosis animal model. Comprising the following steps: after adaptive feeding of healthy mice, intragastric ursodeoxycholic acid is performed once, the mice are fed with high-fat feed and periodically subjected to nasal drop treatment by 50mg / mL SiO2 suspension for more than 10 weeks, and during the period, the mice freely eat and drink water; wherein the specific operation of the periodic 50mg / mL SiO2 suspension nasal drop is as follows: the periodic 50mg / mL SiO2 suspension nasal drop is carried out once every 3-4 days, and 30-50mu L of the periodic 50mg / mL SiO2 suspension nasal drop is taken each time; the intragastric administration dosage of ursodeoxycholic acid is that 100-200 mg of ursodeoxycholic acid is administered to each kilogram of mouse body weight. According to the invention, a triple induction strategy of silicon dioxide exposure, high fat diet and induction factor stimulation is adopted, two pathological characteristics of silicosis and atherosclerosis can be successfully and stably generated in a C57BL / 6J mouse, and relevance of silicosis and atherosclerosis can be simulated at the same time.

The invention discloses an application of an NRF2 signal channel activator in preparation of a medicine for preventing or treating hyperuricemia-related atherosclerosis, relates to the technical field of medicines, and particularly relates to an application of the NRF2 signal channel activator in preparation of a medicine for preventing or treating hyperuricemia-related atherosclerosis. The NRF2 signal channel activator is used for up-regulating NRF2 protein expression or enhancing transcriptional activity of the NRF2 protein; the NRF2 signal channel activator is used for up-regulating expression of a downstream target gene SLC7A11 and / or GPX4 so as to inhibit ferroptosis of hyperuricemia aortic macrophages; the level of glutathione (GSH) in serum is increased; the malondialdehyde (MDA) and / or iron ion (Fe < 2 + >) level in serum is reduced; nRF2 signal channel activation and macrophage ferroptosis inhibition are associated, and the NRF2 signal channel is applied to prevention and treatment medicines for hyperuricemia-related atherosclerosis, so that development of specific treatment medicines for patients suffering from hyperuricemia-related atherosclerosis is facilitated.

The present application relates to a kind of construction method of atherosclerosis humanized mouse model, belong to genetic engineering and genetic modification technical field.The present application is first in ApoE and Ldlr double gene knockout mouse background and obtains NOD-4G gene knockout mouse by knockouting Prkdc and Il2rg gene in mouse, humanized atherosclerosis model is constructed by injecting human umbilical cord blood CD133+stem cell and high-fat feed feeding.Through to atherosclerosis degree analysis, it is found that the aorta and aortic root of the humanized atherosclerosis model constructed have a large number of plaque formation, and contain human CD45 + Leukocyte.This atherosclerosis humanized mouse model provides better animal genetic model for the analysis of the role of human immune cells in the occurrence and development of atherosclerosis disease, and has important significance for the research of human disease and the development of new therapy.

The invention relates to the technical field of novel drug application of compounds, in particular to a compound Man-Tz, a biological orthogonal reaction system and application of the compound Man-Tz. The dTRIM24 is accurately released at the atherosclerotic plaque through a biological orthogonal targeting technology, and the problem of non-specific distribution caused by a traditional administration mode is effectively solved by utilizing the specific reaction of an artificial target point Man-Tz and TCO-dTRIM24-TCO. According to the technology, the TRIM24 protein of 117kDa can be specifically degraded, and macrophages are promoted to be polarized to an anti-inflammatory M2 type by inhibiting Stat6 acetylation, so that plaque formation is inhibited. Experiments prove that the system has concentration and time-dependent effects, drug exposure of non-target tissues is remarkably reduced while efficient degradation activity is maintained, and a novel targeted therapy strategy with high specificity and low toxic and side effects is provided for atherosclerosis treatment.

The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and a preparation method and application thereof. The traditional Chinese medicine composition provided by the invention comprises astragalus membranaceus, cinnamon, semen cassiae, lotus leaves, poria cocos, lophatherum gracile, malt, hawthorn, rose, pogostemon cablin, sophora flower, semen torreya and emblic leafflower fruit. The formula takes the effects of tonifying spleen and promoting diuresis, soothing liver and regulating qi, and removing food retention and dissolving turbidity as the core, and has multiple effects of promoting urination and relieving stasis. The traditional Chinese medicine composition provided by the invention can regulate and control abnormal signal pathways of fatty liver and atherosclerosis; the compound has no obvious inhibition effect on a hepatic cell line HepG2 and has an inhibition effect on a hepatic stellate cell line LX2; the obvious lipid-lowering effect is achieved on a HepG2 high-lipid model; liver fat accumulation and liver injury in a TAA-induced zebrafish fatty liver model can be remarkably improved.

The present invention refers to Annexin A8 (AnxA8) inhibitors, or pharmaceutical composition comprising thereof, for use in a method for the treatment and / or prevention of atherosclerosis. Preferably, the method comprises preventing atherosclerotic plaque formation.

The present application relates to the field of food, health care products and medicine, and specifically relates to a purslane oral composition for regulating blood lipid and resisting atherosclerosis, and a preparation method and application thereof. The present application takes purslane extract, galangal extract and borneol as core components, and realizes the synergistic effects of lipid regulation, anti-inflammation, reduction of plaque area, stabilization of vulnerable plaque, mild anti-thrombus and myocardial protection through scientific proportioning. The bioavailability is significantly improved by combining the tongue sublingual absorption of borneol and the mucosal penetration of galangal volatile oil. The composition has comprehensive targets, definite effects and good safety, and can be made into oral dosage forms such as buccal tablets, dripping pills and oral disintegrating tablets, and is suitable for daily oral care of cardiovascular sub-healthy people.

The invention provides an anti-atherosclerosis lipidosome carrier drug and a preparation method thereof, and belongs to the technical field of biological pharmacy, the lipidosome carrier drug is prepared by taking tussah peptide, premna microphylla leaf flavonoid glycoside, clausena lansium leaf polysaccharide and troxerutin as active ingredients. The antheraea pernyi peptide is a product between 1kDa and 5kDa obtained by extracting protein from antheraea pernyi and sequentially carrying out enzymolysis by bacillus subtilis protease and pepsin. The premna microphylla leaf flavonoid glycoside is prepared by performing enzymolysis and water extraction on premna microphylla leaves and then purifying the premna microphylla leaves through an HPD-600 macroporous adsorption resin column. The clausena lansium leaf polysaccharide is prepared by the following steps: extracting clausena lansium leaves with water, precipitating with ethanol, redissolving, and purifying through a DEAE-52 cellulose column and a Sephadex G-100 gel column in sequence. All the components aim at key pathological links of atherosclerosis respectively, and the core advantages of high efficiency, safety and stability are achieved through multi-component synergistic compatibility and closed-loop optimization of a fine preparation process.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of LGR5 in diagnosis and treatment of vascular calcification. Experiments prove that the key effect of the LGR5 in aortic smooth muscle calcification is found for the first time, it is indicated that the LGR5 is a new target spot for regulating and controlling vascular calcification, meanwhile, vascular calcification can be accurately inhibited through knockdown / knockout of the specific Lgr5 gene of vascular smooth muscle, and meanwhile, vascular calcification can be accurately inhibited through knockout / knockout of the specific Lgr5 gene of the vascular smooth muscle. According to the application disclosed by the invention, the mechanism that the Lgr5 regulates and controls the osteogenic differentiation of the vascular smooth muscle cells through the Wnt / beta-catenin signal channel is preliminarily clarified, and a clear action target and a theoretical basis are provided for drug research and development; the invention provides a new strategy for treatment of diseases such as atherosclerosis and the like, and has a wide clinical application prospect.

The invention relates to an F base modified von Willebrand factor vWF targeting aptamer and an application of the F base modified von Willebrand factor vWF targeting aptamer. Specifically, the invention provides an F base modified vWF targeting aptamer (AF-BT100), the F base modified vWF targeting aptamer comprises a nucleotide core sequence as shown in SEQ ID NO: 1, and the 5'end and the 3 'end are respectively connected with at least two artificial hydrophobic F bases. The invention also comprises a radionuclide-labeled molecular imaging probe [68Ga] Ga-NOTA-AF-BT100, which can realize specific PET imaging in the focus of atherosclerosis, carotid artery thrombosis and acute myocardial infarction. According to the invention, the integrated application of diagnosis and treatment of the pantovascular diseases based on the same vWF targeting aptamer is realized for the first time, and a new strategy is provided for accurate diagnosis and treatment of the pantovascular diseases.

Methods and systems are provided for assessing an area of interest in the circulatory system of a subject. The method comprises: obtaining (210) a temporal sequence of ultrasound image frames of the area of interest; obtaining (220, 320) one or more trained models; inputting (250, 350) the temporal sequence of ultrasound image frames into the one or more trained models; and analysing (260, 360) the temporal sequence of ultrasound image frames, using the one or more trained models, to produce output data characterising a condition of the area of interest, wherein the output data characterises an extent of atherosclerosis or calcification of the area of interest, and wherein the area of interest is the aortic valve. An associated training method for training the one or more models is also provided.

The invention provides application of endometrial mesenchymal stem cell exosomes in atherosclerosis, and belongs to the technical field of biological medicine. The invention provides a bioactive preparation which is derived from specific tissues, has good safety and definite treatment directivity, can effectively intervene in the progress of atherosclerotic plaques and relieve pathological changes of blood vessels, and the treatment convenience and patient tolerance are remarkably improved through a non-invasive administration mode of the bioactive preparation. A brand new solution with excellent application potential is provided for clinical management of atherosclerosis.

The application belongs to the technical field of biological medicine, and particularly relates to a kind of nano-lipid granules for treating atherosclerosis and its preparation method and application, the nano-lipid granules take PLGA encapsulated PDHA1 protein and aggregation-induced emission molecule as core, foam cell membrane is coated on the surface of PLGA, the outermost layer is coated with active oxygen responsive liposome;Aggregation-induced emission molecule is the coupling product of diphenylamine donor unit and benzothiadiazole-thiophene acceptor unit.The present application co-delivers PDHA1 protein and AIE photothermal molecule, homologous targeting of foam cell membrane, active oxygen responsive liposome outer layer and near-infrared two-zone imaging / photothermal therapy function is integrated in a single nano platform, realizes the precise diagnosis of HHcy-AS, metabolic microenvironment repair and photothermal removal of foam cells multimodal synergistic therapy, and provides a new treatment strategy for atherosclerosis, especially high homocysteine related atherosclerosis.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating atherosclerosis and a preparation method thereof. The traditional Chinese medicine composition for treating atherosclerosis is prepared from the following raw materials in parts by weight: 20 to 40 parts of radix astragali seu hedysari, 7 to 10 parts of radix notoginseng, 10 to 20 parts of poria cocos, 5 to 15 parts of lotus leaves, 10 to 15 parts of raw fructus crataegi, 10 to 20 parts of radix salviae miltiorrhizae, 10 to 15 parts of radix angelicae sinensis and 2 to 10 parts of ramulus cinnamomi. The traditional Chinese medicine composition can intervene in the atherosclerosis process through multiple ways of adjusting the blood fat level, improving aorta pathological injury, inhibiting inflammatory response, increasing intestinal flora diversity and the like, and the comprehensive treatment effect of the traditional Chinese medicine composition is equivalent to that of clinical conventional medicine statins.

Everzional carotid endarterectomy represents the main surgical procedure intended for the treatment of atherosclerosis in the carotid arteries. One of the key challenges of this operation is ensuring adequate control of the distal part of the atherosclerotic plaque. Inadequate control in this part of the procedure can result in the retention of small plaque fragments, significantly increasing the risk of postoperative ischemic stroke. To address this issue, our medical instrument allows for better control and reduces the risk of complications after surgery. Our technique involves visual inspection of the hard-to-reach segment of the distal part of the artery using an everzional ring during standard everzional carotid endarterectomy. This innovative approach uses a specially designed ring on a curved support through which the carotid artery is threaded and rotated around the entire circumference of the ring, allowing for more precise and efficient removal of the atherosclerotic plaque.

The invention relates to the technical field of animal models, and particularly discloses a construction method and application of a mouse model with fat dystrophy complicated with atherosclerosis, and the construction method comprises the following steps: mating MED1flox / flox mice with Adipoq-CreERT2 mice to obtain F1-generation mice; the F1-generation mice and MED1flox / flox mice are subjected to backcross, the mice with the genotype being MED1fl / flAdipoq-Cre < + / -> are screened, tamoxifen is injected to induce fat cell specific Cre recombinase expression, and fat cell specific MED1 gene knockout mice are obtained; and performing caudal vein injection of AAV8-PCSK9 virus and feeding with a high-cholesterol and high-fat feed to obtain the fat dystrophy complicated with atherosclerosis mouse model. According to the method provided by the invention, the mouse model with fat dystrophy complicated with atherosclerosis is successfully constructed and obtained, and collaborative simulation and regulation of phenotypes of two diseases are realized.

The invention belongs to the technical field of medicines and disease treatment, and particularly relates to application of SEC24D in preparation of medicines for treating atherosclerosis. The amino acid sequence of the SEC24D is as shown in SEQ ID NO.1. The medicine is a preparation which takes the SEC24D as a target spot and can inhibit the expression of the SEC24D. Clinical data and basic experiments prove that the SEC24D plays an important role in inflammation, the mRNA level of whole blood cells of the SEC24D is increased to reflect the activation of the inflammation, and we find that the mRNA level and protein level of the SEC24D are increased in the polarization process of M1 macrophages, the expression of the macrophages SEC24D is reduced, the functions of the M1 macrophages can be inhibited, and inflammatory mediators can be reduced.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The application discloses an antiatherosclerotic polypeptide of Buthus martensii Karsch and application thereof, and belongs to the technical field of traditional Chinese medicinal material polypeptides. The antiatherosclerotic polypeptide of Buthus martensii Karsch is one of peptide segment 1, peptide segment 2, peptide segment 3, peptide segment 4, peptide segment 5, peptide segment 6 and peptide segment 7, and the amino acid sequences are respectively shown in SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6 and SEQ ID NO. 7. The antiatherosclerotic polypeptide screened by the application can significantly reduce oxidation damage and lipid deposition, especially the peptide segment 5; the application provides a theoretical basis for the medicinal development of the antiatherosclerotic polypeptide of Buthus martensii Karsch and reveals the potential antiatherosclerotic mechanism.

The current disclosure provides sensitive diagnostic methods that do not require invasive angiography. It was found that TNFAIP2 was secreted into the sera of subjects with atherosclerosis. This novel biomarker can be used to detect early-stage atherosclerosis. Accordingly, aspects of the disclosure relate to a method for measuring a TNFAIP2 level comprising: obtaining a biological sample from a subject having, suspected of having, or at risk of having atherosclerosis; and measuring the TNFAIP2 level in a biological sample from the subject as compared to a control. Also disclosed is a method for treating or preventing atherosclerosis in a subject, the method comprising administering an effective amount of a treatment for atherosclerosis to the subject after measuring the TNFAIP2 level in a biological sample from the subject as compared to a control.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The present application belongs to the field of drug screening and biological detection, and particularly relates to a fluorescent probe for screening anti-atherosclerotic traditional Chinese medicines and a preparation method and application thereof. The present application aims to construct an anti-atherosclerotic traditional Chinese medicine screening platform based on fluorescent probe technology, and screen 70 kinds of traditional Chinese medicines. First, a probe for recognizing ONOO⁻ is designed and synthesized as a tool for detecting the ROS content in zebrafish, then a zebrafish atherosclerosis model is constructed by using lipopolysaccharide induction, and the improvement of different traditional Chinese medicine crude extracts on the atherosclerosis in zebrafish is dynamically monitored by using confocal imaging technology. The present application not only provides an innovative method for the efficient screening of anti-atherosclerotic components of traditional Chinese medicines, but also provides potential drug candidates for the prevention and treatment of atherosclerosis.

This invention provides a sea cucumber polypeptide, its preparation method, and its use in the treatment of atherosclerosis. The polypeptides with therapeutic and / or preventive functions for atherosclerosis are SCP-1 and SCP-2, derived from sea cucumbers or synthesized artificially. The preparation method includes pretreatment of sea cucumber raw materials, followed by stepwise enzymatic hydrolysis using neutral protease and papain, and purification via enzyme inactivation, centrifugation, nanofiltration desalting, gel filtration chromatography, and preparative high-performance liquid chromatography. The sea cucumber polypeptide can be used to prepare and / or prevent and treat atherosclerosis, and can also be formulated into pharmaceutical compositions containing pharmaceutically acceptable carriers or excipients, providing a new material basis and effective approach for the treatment of atherosclerosis, with broad application prospects in the pharmaceutical, health product, and food fields.

The invention discloses an atherosclerosis risk assessment kit and an assessment method, the kit takes a proinflammatory-proregression oxidized lipid combination as a detection target, and comprises a core detection assembly, a sample pretreatment assembly and an auxiliary assembly; a specific monoclonal antibody in the core detection assembly has high specificity and high sensitivity, and can accurately and quantitatively detect the concentration of four key oxidized lipids in plasma; the sample pretreatment assembly can effectively remove impurities such as protein in plasma, and the detection accuracy is improved. According to the risk assessment method, early risk early warning of atherosclerosis is realized by calculating a proinflammatory / proregression lipid ratio and combining with each index concentration threshold value. According to the present invention, the proinflammatory-proregression oxidized lipid combination is adopted as the detection target, and the optimized ELISA detection method is combined, such that the early-stage, accurate and rapid risk evaluation can be performed on the atherosclerosis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of IAA in preparation of a medicine for preventing and treating atherosclerosis. Atherosclerosis is caused by excessive deposition of cholesterol, and IAA can significantly reduce formation of aorta and aortic sinus lipid plaques of atherosclerosis model mice by adjusting monocyte chemotactic and adhesion functions (specifically, down-regulating expression of chemotactic factors CCL2 and CXCL1, receptors CCR1 and CCR2, adhesion molecules ICAM1 and the like). An injection preparation is preferably selected as a medicine dosage form, the intervention dosage of IAA is 50 mg / kg, and the intervention time is 15 weeks. The new application of IAA in prevention and treatment of atherosclerosis is explored for the first time, the action mechanism of IAA is clear, the intervention effect is remarkable, and a new target spot and thought are provided for developing safe and effective medicines and means for preventing and treating atherosclerosis.